Last updated on April 2018

Phase II Trial for the Treatment of Relapsed Osteosarcoma

Brief description of study

Phase II randomized study for the comparison of the Gemcitabine plus Docetaxel and the Ifosfamide treatment of patients with relapsed osteosarcoma

Detailed Study Description

Patients with relapsed osteosarcoma will be randomized to receive Gemcitabine plus Docetaxel or High Doses Ifosfamide (continuous infusion) every 3 weeks, up to 6 weeks

Clinical Study Identifier: NCT02718482

Contact Investigators or Research Sites near you

Start Over

Massimo Aglietta, MD

Fondazione del Piemonte per l'Oncologia IRCC Candiolo
Candiolo, Italy
  Connect »

Alessandro Comandone, MD

Ospedale Gradenigo
Torino, Italy
  Connect »

Stefano Ferrari, MD

Istituti Ortopedici Rizzoli - Unit of Chemotherapy of Muscoloskeletal Tumors
Bologna, Italy
  Connect »

Angela Tamburini, MD

A.O. Universitaria Meyer
Firenze, Italy
  Connect »

Alberto Garaventa, MD

Istituto Giannina Gaslini
Genova, Italy
  Connect »

Cristina Meazza, MD

FONDAZIONE IRCCS Istituto Nazionale dei Tumori
Milano, Italy
  Connect »

Fiorina Casale, Prof.

Universit seconda di Napoli
Napoli, Italy
  Connect »

Gianni Bisogno, MD

Azienda Ospedaliera di Padova
Padova, Italy
  Connect »

Virginia Ferraresi, MD

Istituto Regina Elena - IFO
Rome, Italy
  Connect »

Franca Fagioli, MD

Ospedale Infantile Regina Margherita - Unit of Paediatric Oncoematology
Torino, Italy
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.